Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

22.71
+0.89004.08%
Volume:148.58K
Turnover:3.37M
Market Cap:1.46B
PE:-6.55
High:23.01
Open:22.16
Low:22.16
Close:21.82
52wk High:23.01
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.47
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:4.54
PE(LYR):-6.10

Loading ...

Cullinan Says Zipalertinib Plus Chemotherapy Meets PFS Endpoint in Phase 3 Rezilient3 Lung Cancer Trial

Reuters
·
Aug 13

Analysts Are Bullish on These Healthcare Stocks: Mesoblast Limited (MEOBF), Cullinan Management (CGEM)

TIPRANKS
·
Aug 07

Cullinan Maintained at Buy as Advancing Autoimmune and Oncology Pipeline Supports Unchanged $36 Price Target

TIPRANKS
·
Aug 07

Wedbush Adjusts Price Target on Cullinan Therapeutics to $39 From $37, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

Cullinan Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Cullinan Therapeutics Q2 EPS $(0.81) Beats $(0.85) Estimate

Benzinga Earnings
·
Aug 06

Cullinan Therapeutics Q2 Operating Income USD -57.254 Million Vs. IBES Estimate USD -57.1 Million

Reuters
·
Aug 06

Cullinan Q2 FY26 Net Loss Narrows 23.36% to $53.7 Million

Reuters
·
Aug 06

Cullinan Therapeutics Q2 Cash & Investments USD 356 Million

THOMSON REUTERS
·
Aug 06

Cullinan Therapeutics Q2 EPS USD -0.81 VS. Ibes Estimate USD -0.81

THOMSON REUTERS
·
Aug 06

Cullinan Therapeutics Q2 Operating Expenses USD 57.254 Million

THOMSON REUTERS
·
Aug 06

Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 06

Will FDA-Backed Registrational Phase 2 for CLN-049 Redefine Cullinan Therapeutics' (CGEM) Narrative?

Simply Wall St.
·
Aug 03

Cullinan Therapeutics price target raised to $39 from $38 at BTIG

TIPRANKS
·
Jul 29

Cullinan Therapeutics is Maintained at Buy by BTIG

Dow Jones
·
Jul 29

Analysts’ Top Healthcare Picks: Kiniksa Pharmaceuticals (KNSA), Cullinan Management (CGEM)

TIPRANKS
·
Jul 28

Cullinan Therapeutics announces End-of-Phase 1 meeting for CLN-049 with FDA

TIPRANKS
·
Jul 28

Cullinan to Launch Registrational Phase 2 Cln-049 Trial in Relapsed/refractory AML in Q3 2026

Reuters
·
Jul 28

Cullinan Therapeutics - to Initiate Phase 2 Registrational Study of Cln-049 in Aml in Q3 2026

THOMSON REUTERS
·
Jul 28

Cullinan Therapeutics - Phase 2 Study to Include Dose-Optimization and Single-Arm Cohort at Recommended Dose

THOMSON REUTERS
·
Jul 28